 |
市場調查報告書
商品編碼
1684604
嗜酸性食道炎市場機會、成長動力、產業趨勢分析與預測 2025 - 2034Eosinophilic Esophagitis Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 |
||||||
2024 年全球嗜酸性食道炎市值為 3.662 億美元，預計在 2025 年至 2034 年期間將經歷令人印象深刻的 31.4% 的複合年成長率，這得益於這種慢性免疫介導疾病的發病率和患病率的上升。這種成長是由人們認知的提高、治療方案的進步以及早期診斷率的飆升等多種因素所推動的。隨著醫療保健提供者優先考慮 EoE 等罕見疾病的管理，對創新治療解決方案的需求持續上升，為顯著的市場擴張鋪平了道路。
針對性治療，特別是生物製劑和其他尖端藥物類別的開發，透過解決與 EoE 相關的特定發炎途徑改善了患者的治療效果。此外，支持性醫療政策和更多的研發資金正在促進該領域的創新，使 EoE 成為全球治療進步的焦點。
| 市場範圍 | |
|---|---|
| 起始年份 | 2024 |
| 預測年份 | 2025-2034 |
| 起始值 | 3.662 億美元 |
| 預測值 | 56億美元 |
| 複合年成長率 | 31.4％ |
根據藥物類別，市場分為生物製劑、皮質類固醇、質子幫浦抑制劑、免疫調節劑和其他療法。其中，皮質類固醇成為領先細分市場，2024 年貢獻了 1.373 億美元。皮質類固醇在緩解發炎和緩解症狀（例如減輕吞嚥困難和胸部不適）方面已被證實有效，這鞏固了其作為 EoE 管理基石的地位。皮質類固醇因其可靠性和快速產生效果的能力而被廣泛採用，常常作為飲食調整和其他干預措施的補充。
根據給藥途徑，市場分為口服、注射和外用。由於口服給藥方式方便且對患者友好，到 2024 年，口服給藥途徑將佔最大佔有率，達到 41.5%。口服治療因其易於使用而特別受到青睞，這有助於更好地遵守長期管理計劃。口服療法的最新創新，例如先進的生物製劑和針對發炎途徑的小分子藥物，進一步增強了該領域的療效。這些進步不僅改善了症狀控制，也提升了整體患者體驗，為市場的成長做出了重大貢獻。
美國繼續引領全球 EoE 市場，2024 年的估值為 1.513 億美元。推動這一主導地位的因素包括患病率上升（尤其是在兒童和年輕人中），以及先進的診斷和治療解決方案的可用性。中國對罕見疾病和慢性病的管理十分重視，並在創新治療方案方面投入了大量資金。醫療專業人員和患者的意識增強也有助於早期診斷和改善治療效果。
目錄
第 1 章：方法論與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業衝擊力
- 成長動力
- 嗜酸性細胞性食道炎盛行率上升
- 診斷技術的進步
- 標靶藥物治療的發展
- 增加醫療投資
- 產業陷阱與挑戰
- 學名藥的競爭
- 治療費用高昂
- 成長動力
- 成長潛力分析
- 監管格局
- 管道分析
- 波特的分析
- PESTEL 分析
第4章：競爭格局
- 介紹
- 公司矩陣分析
- 主要市場參與者的競爭分析
- 競爭定位矩陣
- 策略儀表板
第 5 章：市場估計與預測：按藥物類別，2021 年至 2034 年
- 主要趨勢
- 生物製劑
- 皮質類固醇
- 質子幫浦抑制劑
- 免疫調節劑
- 其他藥品類
第 6 章：市場估計與預測：按管理路線，2021 年至 2034 年
- 主要趨勢
- 口服
- 注射劑
- 主題
第7章：市場估計與預測：依年齡層，2021 – 2034 年
- 主要趨勢
- 兒科
- 成人
- 老年
第 8 章：市場估計與預測：按配銷通路，2021 年至 2034 年
- 主要趨勢
- 醫院藥房
- 零售藥局
- 網路藥局
第 9 章：市場估計與預測：按地區，2021 年至 2034 年
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
第10章：公司簡介
- Allakos
- Arena Pharmaceuticals
- AstraZeneca
- Cipla
- Ellodi Pharmaceuticals
- EsoCap
- GlaxoSmithKline
- Revolo Biotherapeutics
- Sanofi
- Sun Pharmaceutical
- Takeda Pharmaceutical Company
- Teva Pharmaceutical
The Global Eosinophilic Esophagitis Market, valued at USD 366.2 million in 2024, is projected to experience an impressive CAGR of 31.4% from 2025 to 2034, driven by the rising incidence and prevalence of this chronic immune-mediated condition. This growth is fueled by a combination of increasing awareness, advancements in treatment options, and a surge in early diagnosis rates. As healthcare providers prioritize the management of rare diseases like EoE, the demand for innovative therapeutic solutions continues to rise, paving the way for significant market expansion.
The development of targeted treatments, particularly biologics and other cutting-edge drug classes, has enhanced patient outcomes by addressing the specific inflammatory pathways associated with EoE. Furthermore, supportive healthcare policies and greater funding for research and development are bolstering innovation in this domain, making EoE a focal point of therapeutic advancements globally.
| Market Scope | |
|---|---|
| Start Year | 2024 |
| Forecast Year | 2025-2034 |
| Start Value | $366.2 Million |
| Forecast Value | $5.6 Billion |
| CAGR | 31.4% |
The market is categorized by drug class into biologics, corticosteroids, proton pump inhibitors, immunomodulators, and other therapies. Among these, corticosteroids emerged as the leading segment, contributing USD 137.3 million in 2024. Their proven effectiveness in alleviating inflammation and providing symptom relief, such as reducing dysphagia and chest discomfort, reinforces their position as a cornerstone of EoE management. Corticosteroids are widely adopted due to their reliability and ability to deliver rapid results, often complementing dietary modifications and other interventions.
In terms of route of administration, the market is segmented into oral, injectable, and topical options. The oral route held the largest share at 41.5% in 2024, driven by its convenience and patient-friendly nature. Oral treatments are particularly preferred for their ease of use, which promotes better adherence to long-term management plans. Recent innovations in oral therapies, such as advanced biologics and small-molecule drugs targeting inflammatory pathways, have further enhanced the efficacy of this segment. These advancements not only improve symptom control but also elevate the overall patient experience, contributing significantly to the market's growth.
The United States continues to lead the global EoE market, with a valuation of USD 151.3 million in 2024. Factors driving this dominance include rising prevalence rates, particularly among children and young adults, and the availability of advanced diagnostic and therapeutic solutions. The country's focus on managing rare and chronic diseases has resulted in substantial investments in innovative treatment options. Increased awareness among healthcare professionals and patients alike has also contributed to earlier diagnoses and improved outcomes.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definition
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising prevalence of eosinophilic esophagitis
- 3.2.1.2 Advancement in diagnostic techniques
- 3.2.1.3 Development of target drug therapies
- 3.2.1.4 Increasing healthcare investment
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Competition from generic drugs
- 3.2.2.2 High cost of treatment
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Pipeline analysis
- 3.6 Porter's analysis
- 3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Competitive analysis of major market players
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2034 ($ Mn)
- 5.1 Key trends
- 5.2 Biologics
- 5.3 Corticosteroids
- 5.4 Proton pump inhibitors
- 5.5 Immunomodulators
- 5.6 Other drug class
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)
- 6.1 Key trends
- 6.2 Oral
- 6.3 Injectable
- 6.4 Topical
Chapter 7 Market Estimates and Forecast, By Age Group, 2021 – 2034 ($ Mn)
- 7.1 Key trends
- 7.2 Pediatric
- 7.3 Adult
- 7.4 Geriatric
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)
- 8.1 Key trends
- 8.2 Hospital pharmacies
- 8.3 Retail pharmacies
- 8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 India
- 9.4.3 Japan
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
Chapter 10 Company Profiles
- 10.1 Allakos
- 10.2 Arena Pharmaceuticals
- 10.3 AstraZeneca
- 10.4 Cipla
- 10.5 Ellodi Pharmaceuticals
- 10.6 EsoCap
- 10.7 GlaxoSmithKline
- 10.8 Revolo Biotherapeutics
- 10.9 Sanofi
- 10.10 Sun Pharmaceutical
- 10.11 Takeda Pharmaceutical Company
- 10.12 Teva Pharmaceutical
